mark2017's Stocks to Watch

M

mark2017

Experienced member
Messages
1,282
Likes
24
Hi,
I put very strong stocks of my portfolio

Galaxy Resources, is a Australian mining company.

Undervalued, Price/ eps 11x

Lithium contracts with china
imag

Fagerhult ab. Sweden company in luminarie. Number one in Europe

imagenes gratis

Good finacial Ratios
http://www.4-traders.com/FAGERHULT-AB-16546171/financials/

AUBAY, french IT company . P/EPS 18x
http://www.4-traders.com/AUBAY-TECHNOLOGY-4706/?type_recherche=rapide&mots=AUBAY

subir imagen

Dfds, Danish shipping company, undervalued, p/e 13 x
http://www.4-traders.com/DFDS-A-S-1412874/?type_recherche=rapide&mots=dfds

imag

Regards
 
mark2017 said:
Hi,
I put very strong stocks of my portfolio

Galaxy Resources, is a Australian mining company.

Undervalued, Price/ eps 11x

Lithium contracts with china
imag

Fagerhult ab. Sweden company in luminarie. Number one in Europe

imagenes gratis

Good finacial Ratios
http://www.4-traders.com/FAGERHULT-AB-16546171/financials/

AUBAY, french IT company . P/EPS 18x
http://www.4-traders.com/AUBAY-TECHNOLOGY-4706/?type_recherche=rapide&mots=AUBAY

subir imagen

Dfds, Danish shipping company, undervalued, p/e 13 x
http://www.4-traders.com/DFDS-A-S-1412874/?type_recherche=rapide&mots=dfds

imag

Regards
Click to expand...

Financial Ratios:

INDUTRADE AB
P/E ratio (Price / EPS) 22,9x
Capitalization / Revenue 1,68x
EV / Revenue 1,95x 1,79x
EV / EBITDA 14,8x 13,4x
ROA (Net Profit / Asset) 10,6%
ROE (Net Profit / Equities) 22,4%
Rate of Dividend 42,1% 43,3%
Cash Flow / Sales 8,68%
Financial Leverage (Net Debt / EBITDA) 2,05x

http://www.4-traders.com/INDUTRADE-AB-6498214/financials/

AUBAY

P/E ratio (Price / EPS) 19,9x

EV / EBITDA 11,0x 10,1x

operating Leverage (Delta EBIT / Delta Sales) 0,88x
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) 16,5%
Rate of Dividend 27,1%

CAPEX / CA 0,61% 0,59%
Cash Flow / Sales 6,61%
-
Financial Leverage (Net Debt / EBITDA) -0,33x
http://www.4-traders.com/AUBAY-TECHNOLOGY-4706/financials/

FAGERHULT AB

P/E ratio (Price / EPS) 25,6x 23,0x
Capitalization / Revenue 2,37x 2,15x

EV / EBITDA 17,7x 15,0x
Yield (DPS / Price) 1,49%

Operating Margin (EBIT / Sales) 12,3%
operating Leverage (Delta EBIT / Delta Sales) 2,67x

ROA (Net Profit / Asset) 12,1%
ROE (Net Profit / Equities) 26,0%
Rate of Dividend 38,3% 38,5%

CAPEX / CA 2,92% 2,85%
Cash Flow / Sales 9,99% 11,0%

Financial Leverage (Net Debt / EBITDA) 1,98x

http://www.4-traders.com/FAGERHULT-AB-16546171/financials/


DFDS
P/E ratio (Price / EPS) 13,4x 12,8x
Capitalization / Revenue 1,46x 1,39x
EV / Revenue 1,58x 1,46x
EV / EBITDA 8,40x 7,98x
Yield (DPS / Price) 1,71% 1,69%


operating Leverage (Delta EBIT / Delta Sales) 15,2x

ROA (Net Profit / Asset) 12,2%
ROE (Net Profit / Equities) 22,7%
Rate of Dividend 22,8% 21,6%

CAPEX / CA 6,87% 11,1%
Cash Flow / Sales 17,1% 17,2%

Financial Leverage (Net Debt / EBITDA) 0,64x
 
Fagerhult ab,
Greater future benefits with linear leds
To strategically strengthen the Fagerhult Group's position in the professional outdoor lighting market, Fagerhult has signed an agreement to acquire 100% of the shares in WE-EF based in Bispingen, Germany. This acquisition takes the Group's sales in the outdoor segment to a run-rate exceeding 100 MEUR. The acquisition is expected to have a positive effect on the earnings per share during 2017 and forward.

http://www.prnewswire.com/news-releases/fagerhult-signs-an-agreement-to-acquire-we-ef-300383462.html
 
Think Childcare Limited currently owns, manages and operates 37 long day childcare facilities in Australia for children between the ages of six weeks and six years old. Think Childcare Limited’s strategy is to acquire and integrate childcare centres identified on the basis of strict acquisition criteria and to optimise the performance of centres that it owns and manages to increase their profitability via:

http://www.thinkchildcare.com.au/investors

subir gif
 
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Bayer is improving people’s quality of life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of high-quality food, feed and plant-based raw materials.
[​IMG]
An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.
We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.

Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.

We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.


http://www.investor.bayer.de/en/bayer-group/ueberblick/key

Latest Report

Core earnings per share
€1.73 (+2.4%)
Group sales
€11.3 billion (+3.5%)

http://www.quarterly-report-2016-q3.bayer.com/

Financial ratios

http://www.4-traders.com/BAYER-AG-436063/financials/


Column 1 Column 2 Column 3
P/E ratio (Price / EPS) 18,3x 16,2x
Capitalization / Revenue 1,87x 1,80x
EV / Revenue 2,20x 2,04x
EV / EBITDA 9,26x 8,49x
Yield (DPS / Price) 2,53% 2,71%
Price to book (Price / BVPS) 3,27x 2,94x
Column 1 Column 2 Column 3
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 18,6% 19,7%
operating Leverage (Delta EBIT / Delta Sales) - 2,40x
Net Margin (Net Profit / Revenue) 10,2% 11,2%
ROA (Net Profit / Asset) 7,65% 8,64%
ROE (Net Profit / Equities) 22,1% 21,5%
Rate of Dividend 46,3% 44,0%
Column 1 Column 2 Column 3
Balance Sheet Analysis 2016e 2017e
CAPEX / CA 5,53% 5,31%
Cash Flow / Sales 17,8% 17,0%
Capital Intensity (Assets / Sales) 1,33x 1,30x
Financial Leverage (Net Debt / EBITDA) 1,37x

imagenes gratis
 
Products for the Health of Humans, Animals and Plants

Bayer’s broad product portfolio includes many world-famous brands which have shaped the iconic Bayer brand. With our products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Bayer is improving peo*ple’s quality of life by preventing, alleviating and curing diseases. And we are helping to provide a reliable supply of high-quality food, feed and plant-based raw materials.
Some of our products have been helping our customers for decades; others only recently came out of our labs. Their active ingredients are designed to influence the biochemical processes in living organisms. As different as people, animals and plants might seem, common rules govern the molecular mechanisms in all life forms. The active ingredients promote or enable positive processes or they prevent or suppress negative processes. That’s what Life Science is all about. And with our innovative products, we help to make life better.
Pharmaceuticals

The Pharmaceuticals product portfolio focuses on:

Prescription products, especially for cardiology and women’s healthcare
Specialty therapeutics in the areas of oncology, hematology and ophthalmology
Radiology: contrast-enhanced diagnostic imaging equipment and the necessary contrast agents
Find our most known Pharmaceuticals brands in our product list
Consumer Health

The Consumer Health product portfolio contains mainly non-prescription products in the following categories:

dermatology
nutritionals
analgesics
gastrointestinals
allergy
cough and cold
foot care
sun care
cardiovascular risk prevention

These products include globally known brands such as Aleve™, Alka Seltzer™, Aspirin™, Bepanthen™/Bepanthol™, Berocca™, Canesten™, Claritin™, Coppertone™, Dr. Scholl’s™, Elevit™, Iberogast™, MiraLAX™, One-A-Day™, Rennie™ and Redoxon™.
Find our most known Consumer Health brands in our product list
Crop Science

Crop Science’s product portfolio focuses on:

high-value seeds
innovative chemical and biological pest management solutions
extensive customer service for modern and sustainable agriculture
Find our most known Crop Science brands in our product list
Animal Health

Animal Health offers products for:

farm animals
companion animals
Find our most known Animal Health brands in our product list

https://www.bayer.com/en/product-portfolio-of-bayer.aspx
http://www.xarelto-info.co.uk/
 
HomePress
Indutrade acquires Sunflower Medical Ltd

2017-01-19 14:00

Indutrade today signed an agreement to acquire all of the shares in Sunflower Medical Ltd (www.sunflowermedical.co.uk), with annual sales of approximately GBP 4.5 million.

Sunflower Medical is a leading UK manufacturer of healthcare equipment. Their product portfolio ranges from medicine dispense cabinets to specialty equipment for examination rooms. Customers are primarily Doctors surgeries, healthcare centers and hospitals.

Possession takes place today and Sunflower Medical will be part of Indutrade’s Special Products business area.

The acquisition is expected to have a marginally positive impact on Indutrade’s earnings per share.

Stockholm, 19 January 2017

INDUTRADE AB (publ)
 
You must log in or register to reply here.

Similar threads

M
mark2017's Commodities to Watch
6 7 8
Replies
146
Views
36K
mark2017
M
Top